An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor

16Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background and purpose: Based on their pharmacological target, two classes of calcitonin-gene-related peptide (CGRP) monoclonal antibodies (mAbs) have been identified: antibodies against the CGRP ligand—galcanezumab, fremanezumab, eptinezumab—and antibodies against the CGRP receptor (CGRP-R), erenumab. The aim of the present study was to compare anti-CGRP versus anti-CGRP-R mAbs in patients with high frequency episodic and chronic migraine. Methods: All patients on monthly treatment with anti-CGRP mAbs with an available 6 months’ follow-up at January 2022 were included. Data on efficacy outcome were collected following one (T1), three (T3) and six (T6) months of treatment, and included monthly headache/migraine days, the Migraine Disability Assessment Scale (MIDAS) and Headache Impact Test 6 (HIT-6) scores, pain intensity, analgesics consumption and response rates (>50% headache days reduction compared to baseline). Results: In all, 152 patients were enrolled, of whom 68 were in treatment with anti-CGRP mAbs (49 galcanezumab, 19 fremanezumab) and 84 with the anti-CGRP-R (erenumab). MIDAS scores were significantly lower in the anti-CGRP group at T1 and T3 (respectively p < 0.02 and p < 0.03) as well as the number of mean migraine days at T3 (p < 0.01). At T3 and T6 outcome measures were comparable, although a significantly higher percentage of super-responders was found in the anti-CGRP group (respectively p < 0.04 and p < 0.05), with a similar overall percentage of responders. Conclusions: The present study on a real-world sample confirms the beneficial effect of both anti-CGRP and anti-CGRP-R mAbs, with a more favorable outcome for anti-CGRP antibodies.

References Powered by Scopus

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

4580Citations
N/AReaders
Get full text

Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial

462Citations
N/AReaders
Get full text

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

459Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response

39Citations
N/AReaders
Get full text

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review

18Citations
N/AReaders
Get full text

Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Schiano di Cola, F., Bolchini, M., Ceccardi, G., Caratozzolo, S., Liberini, P., Rao, R., & Padovani, A. (2023). An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor. European Journal of Neurology, 30(6), 1764–1773. https://doi.org/10.1111/ene.15761

Readers over time

‘23‘24‘25036912

Readers' Seniority

Tooltip

Researcher 3

75%

PhD / Post grad / Masters / Doc 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

57%

Pharmacology, Toxicology and Pharmaceut... 2

29%

Chemistry 1

14%

Save time finding and organizing research with Mendeley

Sign up for free
0